- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02517905
Evaluation of EXPAREL for Prolonged Postsurgical Analgesia in Subjects Undergoing Third Molar Extraction
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Local Administration of EXPAREL for Prolonged Postsurgical Analgesia in Subjects Undergoing Third Molar Extraction
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Subjects will be screened within 30 days prior to surgery.
Randomized subjects will receive a dental nerve block with lidocaine 2% with epinephrine 1:100,000 before undergoing bilateral third molar extraction under local anesthesia. In addition to the lidocaine nerve block, the Investigator may choose to add topical benzocaine or intraoperative nitrous oxide.
At the end of surgery, and at least 20 minutes after the lidocaine administration, blinded study drug will be infiltrated to provide postsurgical analgesia. Subjects will be required to remain in the research facility for 96 hours after study drug administration.
Postsurgical efficacy, safety, and pharmacokinetic (PK) assessments will be conducted.
All subjects will return for a follow-up visits on Days 7 and 10. A phone call will be made to each subject on Day 30 for an adverse event (AE) assessment and to inquire as to whether the subject made any unscheduled phone calls or office visits related to pain.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
Utah
-
Salt Lake City, Utah, United States, 84124
- Jean Brown Research
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female, ≥18 years of age at screening.
- Scheduled to undergo bilateral third molar extractions (i.e., extraction of all four third molars) under local anesthesia. At least one lower mandibular third molar must involve full or partial bony impaction confirmed by visual or radiological evidence.
- American Society of Anesthesiology (ASA) physical status 1, 2, or 3.
- Female subjects must be either surgically sterile, using a medically acceptable method of birth control, or at least 2 years postmenopausal, and must have a documented negative pregnancy test result during screening and on Day 1 prior to surgery.
- Able to provide informed consent, adhere to the study visit schedule, and complete all study assessments.
Exclusion Criteria:
- History of hypersensitivity or idiosyncratic reaction to amide-type local anesthetics or opioids.
- Contraindication to lidocaine, epinephrine, bupivacaine, or oxycodone.
- History of significant drug allergy (e.g., anaphylaxis or hepatotoxicity).
- Positive test result from the urine drug screen at screening or prior to the surgical procedure.
- Currently pregnant, nursing, or planning to become pregnant during the study or within 1 month after study drug administration.
- History or active psychiatric illness (including major depression, bipolar disorder, or anxiety); Type 1 or Type 2 diabetes; severe renal or hepatic impairment; significant cardiovascular disease (including cardiac rhythm disturbance); migraine headaches, frequent headaches, other pain conditions, or other medical condition that, in the opinion of the Investigator, may increase the risk of surgery or interfere with the evaluation of the study drug.
- History of infection requiring intravenous (IV) antibiotics within 45 days or oral (PO) antibiotics within 30 days prior to study drug administration for reasons other than dental prophylaxis. Subjects must be afebrile, without signs or symptoms indicative of active infection.
- Use of any of the following medications within the times specified before surgery: long-acting opioid medication, nonsteroidal anti-inflammatory drugs (NSAIDs), aspirin (except for low-dose aspirin used for cardioprotection), or acetaminophen within 3 days, or any opioid medication within 24 hours.
- Initiation of treatment with any of the following medications within 1 month of EXPAREL infiltration or if the medication(s) are being given to control pain: selective serotonin reuptake inhibitors (SSRIs), selective norepinephrine reuptake inhibitors (SNRIs), gabapentin, pregabalin (Lyrica®), or duloxetine (Cymbalta®). If a subject is taking one of these medications for a reason other than pain control, he or she must be on a stable dose for at least 1 month prior to EXPAREL administration.
- Current use of systemic glucocorticosteroids within 1 month of enrollment in this study.
- Use of any concurrent therapy that could interfere with the evaluation of efficacy or safety, such as any drugs which in the Investigator's opinion may exert significant analgesic properties or act synergistically with the investigational product.
- Administration of an investigational drug within 30 days or 5 elimination half-lives of such investigational drug, whichever is longer, prior to study drug administration, or planned administration of another investigational product or procedure during the subject's participation in this study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: EXPAREL 133 mg
10 mL EXPAREL (bupivacaine liposome injectable suspension) injected into the maxilla (4 mL; 2 mL per side) and mandible (6 mL; 3 mL per side) at the end of surgery and ≥20 min after lidocaine administration
|
Local administration
Other Names:
|
Placebo Comparator: Placebo
10 mL normal saline injected into the maxilla (4 mL; 2 mL per side) and mandible (6 mL; 3 mL per side) at the end of surgery and ≥20 min after lidocaine administration
|
Local administration
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Area Under the Curve (AUC) of Numeric Rating Scale (NRS) Pain Intensity Scores Through 48 Hours
Time Frame: 0-48 hours
|
AUC of NRS pain intensity scores through 48 hours.
Pain intensity scores were measured on a 10-point scale (0=no pain and 10=worst possible pain)
|
0-48 hours
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Area Under the Curve (AUC) of Numeric Rating Scale (NRS) Pain Intensity Scores Through 24 Hours
Time Frame: 0-24 hours
|
AUC of NRS pain intensity scores through 24 hours.
Pain intensity scores were measured on a 10-point scale (0=no pain and 10=worst possible pain) 0-24 hours
|
0-24 hours
|
Area Under the Curve (AUC) of Numeric Rating Scale (NRS) Pain Intensity Scores Through 72 Hours
Time Frame: 0-72 hours
|
AUC of NRS pain intensity scores through 72 hours.
Pain intensity scores were measured on a 10-point scale (0=no pain and 10=worst possible pain)
|
0-72 hours
|
Percentage of Opioid-free Subjects Through 24 Hours.
Time Frame: 0-24 hours
|
Percentage of opioid-free subjects through 24 hours.
|
0-24 hours
|
Percentage of Opioid-free Subjects Through 48 Hours.
Time Frame: 0-48 hours
|
Percentage of opioid-free subjects through 48 hours.
|
0-48 hours
|
Percentage of Opioid-free Subjects Through 72 Hours.
Time Frame: 0-72 hours
|
Percentage of opioid-free subjects through 72 hours.
|
0-72 hours
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Director: Jim Jones, MD, PharmD, Pacira Pharmaceuticals, Inc
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 402-C-329
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Dental Pain
-
Organon and CoCompleted
-
University of ZurichCharite University, Berlin, Germany; First Teaching Hospital of Tianjin University...CompletedExperimental Dental PainSwitzerland
-
GlaxoSmithKlineCompletedPost-surgical Dental PainUnited States
-
Cairo UniversityUnknown
-
Johnson & Johnson Consumer Inc., McNeil Consumer...Johnson & Johnson Consumer and Personal Products WorldwideCompleted
-
Johnson & Johnson Consumer Inc., McNeil Consumer...CompletedPost-operative Dental PainUnited States
-
Novartis PharmaceuticalsCompleted
-
GlaxoSmithKlineCompletedPost-surgical Dental PainUnited States
-
PfizerTerminatedPost-surgical Dental PainUnited States
Clinical Trials on Bupivacaine liposome
-
Nicklaus Children's Hospital f/k/a Miami Children...Terminated
-
Northwell HealthCompletedPost-operative PainUnited States
-
Pacira Pharmaceuticals, IncCompletedHallux Valgus | BunionectomyUnited States
-
Broward HealthCompleted
-
Pacira Pharmaceuticals, IncCompletedPostoperative PainUnited States
-
Catherine Vandepitte, M.D.Pacira Pharmaceuticals, IncCompletedDupuytren's Contracture of the Hand (Viking's Disease)Belgium
-
Shiyou WeiCompleted
-
University of MinnesotaCompleted
-
University of Massachusetts, WorcesterWithdrawnPain, Postoperative | Shoulder Pain | Osteoarthritis of the ShoulderUnited States
-
OSF Healthcare SystemUniversity of Illinois College of Medicine at PeoriaCompletedHip Disease